The earnings call mostly highlighted successful clinical trial results, strong regulatory progress, and readiness for commercial launch, indicating a positive outlook for apitegromab's future. However, observations at CDMO sites by the FDA represent a challenge that needs to be addressed. Overall, the sentiment is cautiously optimistic.

Company Guidance -

Q3 2025

During the Scholar Rock Second Quarter 2025 Business Update Conference Call held on August 6, 2025, several key metrics and guidance were provided. Scholar Rock is focused on three core priorities: achieving regulatory approvals for apitegromab, expanding its use into additional rare neuromuscular diseases, and maintaining disciplined capital allocation. The company is preparing for the U.S. commercial launch of apitegromab, with a priority review and a target action date of September 22, 2025, and plans to launch in Europe starting with Germany in 2026. The BLA for apitegromab has been accepted under priority review by the FDA, and the MAA has been filed with the European Medicines Agency. Scholar Rock reported a strong financial position with $295 million in cash and expects to extend its runway into 2027. The company also anticipates drawing an additional $50 million from its debt facility and receiving $16 million from warrant exercises. The EMBRAZE proof-of-concept study met its primary endpoint, and the company is on track to initiate the Phase II OPAL Trial in young children and explore new indications for apitegromab by the end of 2025.

Regulatory Progress for Apitegromab

The BLA for apitegromab has been accepted under priority review by the FDA with a target action date of September 22, 2025. The company is also working towards potential approval in Europe by mid-2026.

Positive Clinical Trial Results

The SAPPHIRE trial showed statistically significant improvement in motor function in SMA patients, and the Phase II EMBRAZE study met its primary endpoint, demonstrating a 54% greater lean mass preservation with an encouraging safety profile.

Commercial Launch Preparations

The U.S. customer-facing team is fully on board and trained, ready to launch apitegromab following FDA approval. Preparations for a European launch are also underway for 2026.

Financial Position and Runway

Scholar Rock ended the quarter with $295 million in cash, with an anticipated runway into 2027. Additional funding options include a $50 million debt facility and expected $16 million from warrant exercises.

Scholar Rock Holding (SRRK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRRK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.82 / -	-0.66	―	―	―
Aug 06, 2025	2025 (Q2)	-0.67 / -0.98	-0.6	-63.33% (-0.38)
May 14, 2025	2025 (Q1)	-0.68 / -0.67	-0.59	-13.56% (-0.08)
Feb 27, 2025	2024 (Q4)	-0.60 / -0.62	-0.498	-24.50% (-0.12)
Nov 12, 2024	2024 (Q3)	-0.58 / -0.66	-0.53	-24.53% (-0.13)	―
Aug 08, 2024	2024 (Q2)	-0.59 / -0.60	-0.47	-27.66% (-0.13)
May 07, 2024	2024 (Q1)	-0.48 / -0.59	-0.49	-20.41% (-0.10)	―	―
Mar 19, 2024	2023 (Q4)	-0.47 / -0.50	-0.44	-13.18% (-0.06)	―	―
Nov 07, 2023	2023 (Q3)	-0.50 / -0.53	-0.55	3.64% (+0.02)	―
Aug 09, 2023	2023 (Q2)	-0.53 / -0.47	-1.06	55.66% (+0.59)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRRK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$36.98	$34.62	-6.38%
May 14, 2025	$31.40	$30.54	-2.74%
Feb 27, 2025	$37.02	$35.96	-2.86%
Nov 12, 2024	$28.15	$26.66	-5.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Scholar Rock Holding Corp (SRRK) report earnings?

Scholar Rock Holding Corp (SRRK) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Scholar Rock Holding Corp (SRRK) earnings time?

Scholar Rock Holding Corp (SRRK) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SRRK EPS forecast?

SRRK EPS forecast for the fiscal quarter 2025 (Q3) is -0.83.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing